---
schema_version: "secwatch.filing_event.v1"
accession: "0001846253-24-000086"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:12:27.488290+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q3 2024 revenue $4.2M (down 24% YoY), net loss $16.4M; partner pipeline grows

## Summary
- Q3 2024 revenue $4.2M (down 24% YoY); net loss $16.4M ($0.16/sh) vs $15.7M ($0.16/sh) in Q3 2023.
- Cash $59.4M at Sept 30; sold 2.0M shares via ATM for $8.5M in Q3, plus $2.9M post-quarter.
- FY 2024 total opex expected slightly below 2023; FY 2024 cash balance guided at $50-60M.
- Entered three new platform licenses in Q3 (92Bio, MSKCC, Queen Mary London) plus Incyte after quarter.
- Partner events: Immunovant IMVT-1402 IND cleared in RA; Genmab to start Ph3 for acasunlimab; CStone sugemalimab UK approval.

## SEC filing metadata
- accession: 0001846253-24-000086
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/0001846253-24-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000184625324000086/oabi-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001846253-24-000086
- JSON: https://secwatch.observer/filing/0001846253-24-000086.json
- Plain text: https://secwatch.observer/filing/0001846253-24-000086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.